: Increase in cash and cash equivalents of THB 985.00 million, causing from - proceeds from capital increase in ordinary shares net with payments for share issue costs of THB 1,675.28 million.; - net cash
Baht 390,549,286, by the issuance of 220,500,000 newly issued ordinary shares at a par value of Baht 1.00 per share to accommodate the allocation of the newly issued ordinary shares under the specific
reduction of 89,200,714 unissued shares of the Company at a par value of Baht 1.00 per share, reserved for the exercise of warrants to purchase ordinary shares no. 1, issued and offered to the existing
14,000,000 of its registered capital in order to have registered capital at THB 15,000,000 (as per details set out below). 2 For the acquisition of Leyland’s ordinary shares, the share purchase price was
driven by the increase in Retain earnings of Baht 1,974.6 million and Share premium on ordinary shares of Baht 2,557.8 million. As at 31 December 2017, the Company’s Debt-to-Equity ratio was 0.70x
Company has paid dividend from the profit for the year 2018 of Baht 0.17 per share of 540,000,000 ordinary shares, or a total of Baht 91.8 million. Liquidity and capital adequacy As at 30 June 2019 and 31
of the Company and its subsidiaries amounting to THB 200.89 million. Moreover, the Company has paid dividend from the profit for the year 2018 of Baht 0.17 per share of 540,000,000 ordinary shares, or
67.37 94.72 27.35 40.60% Income tax expenses 59.19 65.40 6.21 10.49% Net profit 227.68 252.81 25.13 11.04% Net profit ratio (ROS) 16.00% 14.78% Earnings per share (Baht) 0.37 0.42 0.05 13.51% Total
Characteristics of the Transaction: The company will purchase 100% of the ordinary shares of Modern Pharma Company Limited in accordance to the agreement in the Share Purchase Agreement. Prior to proceeding with
) 2018 % 2017 % 2016 % SHAREHOLDERS’ EQUITY SHARE CAPITAL Authorized share capital 120,000,000 ordinary shares of Baht 1.00 each 120.00 1.66 120.00 1.70 120.00 1.80 Issued and paid-up share capital